Biomoda, Inc. Retains E & E Communications to Assist with Investor and Public Relations

ALBUQUERQUE, N.M., April 26, 2007 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD - News), Albuquerque, New Mexico, (http://www.biomoda.com) , maker of patented early lung cancer detection testing and other cancer diagnostic technology, today announced that it has retained E & E Communications, Laguna Hills, California, to assist with its investor and public relations efforts.

John Cousins, President of Biomoda, said “the Biomoda story is an excellent one and our achievements need wider distribution to potential investors and others.  E & E Communications has a track record of success in doing that work.”

“We are looking forward to helping this excellent company, with its life-saving products and technologies,” said Paul Knopick. Principal, E & E Communications.  “We are impressed with the Biomoda management team and business strategies.”

 Biomoda's patented technology, a non-invasive cytology based lung cancer diagnostic assay, is currently being analyzed at the famous Mayo Clinic in Rochester, Minnesota.  The technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope. The patented technology is designed for cancer screening at an early stage for large populations at a very affordable cost. Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined for whom lung cancer is diagnosed is 15 percent. The survival rate for cases detected when the disease is still localized is 50 percent, however, presently, only 16 percent of lung cancer cases are diagnosed early.

“Safe Harbor” Statement:This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from expectations contained herein. Biomoda is under no obligation to (and expressly disclaims any such obligation) to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise